{"entity":{"id":"nct07715396","kind":"trial","name":"Addition of Platinum-based Chemotherapy to Tislelizumab in PD-L1high Metastatic Non-small Cell Lung Cancer With a High Tumor Burden","aka":["High Five"],"tldr":"A phase 3 trial of tislelizumab and pembrolizumab in lung cancer, run by AIO-Studien-gGmbH, not yet recruiting.","summary":"Addition of Platinum-based Chemotherapy to Tislelizumab in PD-L1high Metastatic Non-small Cell Lung Cancer With a High Tumor Burden is a phase 3, randomised interventional study registered as NCT07715396 by AIO-Studien-gGmbH, with a registry enrolment figure of 230 participants, started 2026-10-30 and due to reach its primary completion in 2031-10-30. Interventions recorded: Tislelizumab; Tislelizumab Combined With Chemotherapy; Pembrolizumab. Conditions listed: Non-small Cell Lung Cancer Metastatic. Primary outcome: Progression-free survival. Lung eligibility wording from the registry: \"Histologically confirmed and treatment-naïve non-small cell lung cancer UICC 9th stage IV\". Sites: Germany. No results are recorded here; the registry entry is the source.","status":"planned","asOf":"2026-09-25","links":[{"label":"ClinicalTrials.gov NCT07715396","url":"https://clinicaltrials.gov/study/NCT07715396"}],"tags":["ctgov-ingest","lung-deep-dive"],"related":[],"cancers":["nsclc"],"sections":[],"technologies":["checkpoint-inhibitor"],"targets":[],"drugs":["tislelizumab","pembrolizumab"],"companies":["beone"],"institutions":[],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"nct":"NCT07715396","phase":"3","setting":"Addition of Platinum-based Chemotherapy to Tislelizumab in PD-L1high Metastatic Non-small Cell Lung Cancer With a High Tumor Burden","sponsor":"AIO-Studien-gGmbH","enrolled":230,"enrolledBasis":"registry","outcomes":[]},"route":"/trials/nct07715396/","neighbours":{"cancer":[{"id":"nsclc","kind":"cancer","name":"Non-small-cell lung cancer","route":"/cancers/nsclc/"}],"technology":[{"id":"checkpoint-inhibitor","kind":"technology","name":"Immune checkpoint inhibitors","route":"/technologies/checkpoint-inhibitor/"}],"drug":[{"id":"pembrolizumab","kind":"drug","name":"Pembrolizumab","route":"/drugs/pembrolizumab/"},{"id":"tislelizumab","kind":"drug","name":"Tislelizumab","route":"/drugs/tislelizumab/"}],"company":[{"id":"beone","kind":"company","name":"BeOne Medicines (formerly BeiGene)","route":"/companies/beone/"}],"term":[{"id":"lung-trials-open-today","kind":"term","name":"Lung cancer trials open today (registry snapshot)","route":"/terms/lung-trials-open-today/"}]}}